BioNTech (NASDAQ:BNTX) PT Lowered to $197.00

BioNTech (NASDAQ:BNTXGet Rating) had its price target reduced by analysts at Morgan Stanley from $217.00 to $197.00 in a research note issued on Tuesday, Marketbeat Ratings reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley’s target price points to a potential upside of 9.82% from the company’s previous close.

BNTX has been the subject of a number of other reports. Canaccord Genuity Group lowered their price target on shares of BioNTech from $450.00 to $300.00 and set a “buy” rating for the company in a report on Tuesday, April 5th. TheStreet downgraded shares of BioNTech from a “c” rating to a “d+” rating in a report on Tuesday, March 1st. Deutsche Bank Rese… set a $200.00 price target on shares of BioNTech in a report on Friday, April 1st. Zacks Investment Research downgraded shares of BioNTech from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 27th. Finally, Redburn Partners upgraded shares of BioNTech from a “sell” rating to a “neutral” rating in a report on Tuesday, February 1st. Eight equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, BioNTech has an average rating of “Hold” and an average target price of $259.59.

NASDAQ:BNTX opened at $179.38 on Tuesday. The company has a current ratio of 4.33, a quick ratio of 4.18 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $160.68 and a two-hundred day moving average price of $220.41. BioNTech has a twelve month low of $121.32 and a twelve month high of $464.00. The company has a market capitalization of $43.50 billion, a P/E ratio of 3.84 and a beta of -0.69.

BioNTech (NASDAQ:BNTXGet Rating) last posted its earnings results on Wednesday, March 30th. The company reported $12.18 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $7.44 by $4.74. BioNTech had a net margin of 54.20% and a return on equity of 142.70%. The firm had revenue of $5.53 billion during the quarter, compared to the consensus estimate of $3.83 billion. During the same period last year, the firm posted $1.87 EPS. The firm’s revenue for the quarter was up 1501.8% on a year-over-year basis. On average, equities research analysts predict that BioNTech will post 32.69 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in BNTX. Spire Wealth Management lifted its position in BioNTech by 2,382.5% during the third quarter. Spire Wealth Management now owns 993 shares of the company’s stock valued at $271,000 after buying an additional 953 shares in the last quarter. Compagnie Lombard Odier SCmA lifted its position in BioNTech by 82.7% during the third quarter. Compagnie Lombard Odier SCmA now owns 44,699 shares of the company’s stock valued at $12,427,000 after buying an additional 20,234 shares in the last quarter. Signaturefd LLC acquired a new position in shares of BioNTech during the third quarter worth $172,000. Commerzbank Aktiengesellschaft FI lifted its position in shares of BioNTech by 2.2% during the third quarter. Commerzbank Aktiengesellschaft FI now owns 3,852 shares of the company’s stock worth $1,052,000 after purchasing an additional 82 shares in the last quarter. Finally, APEIRON CAPITAL Ltd acquired a new position in shares of BioNTech during the third quarter worth $5,624,000. 15.13% of the stock is currently owned by hedge funds and other institutional investors.

About BioNTech (Get Rating)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors.

Read More

Analyst Recommendations for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.